Clinical Trial

Essential Pro Study ( rEPIC04E-HK )

Study acronym: rEPIC04E-HK
Recruiting
View on ClinicalTrials.gov →
Summary
Single center, prospective, non-randomized, post-market clinical follow-up (PMCF) study to confirm and support the clinical safety and performance of Essential Pro to meet EU Medical Device regulation (MDR) requirements in all the CONSECUTIVE patients treated with Essential Pro.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-10-04; most recent amendment 2026-02-12.
Status change: Not Yet Recruiting → Recruiting 2025-06-20
Trial Details
NCT Number NCT06631157
Lead Sponsor Fundación EPIC
Conditions Coronary Artery Disease, Ischemic Heart Disease
Enrollment 100 participants
Start Date 2025-05-15
Primary Completion 2026-11-01 (estimated)
Study Completion 2026-11-01 (estimated)
Updated on ClinicalTrials.gov 2026-02-17